Holographic monitoring method and system for pharmaceutical suppliers based on risk assessment

Through a holographic monitoring method based on risk assessment, comprehensive monitoring and risk assessment are carried out on pharmaceutical suppliers, solving the problem that existing technology cannot effectively evaluate pharmaceutical suppliers, achieving scientific grading and risk identification, and improving the accuracy and efficiency of monitoring.

CN119417240BActive Publication Date: 2025-03-28BEIJING YAOYUN DATA TECH CO LTD
3 Cites 0 Cited by

Patent Information

Application Number
CN202510018734.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-01-07
Publication Date
2025-03-28
Estimated Expiration
2045-01-07

AI Technical Summary

Technical Problem

Existing monitoring methods for pharmaceutical suppliers cannot effectively evaluate pharmaceutical suppliers in multiple dimensions, making it difficult to achieve scientific grading and risk assessment.

Method used

A holographic monitoring method based on risk assessment is adopted to collect and preprocess the risk control data of pharmaceutical suppliers, establish risk type characteristic data, and use flood optimization algorithm and deep search algorithm to perform risk type search and weight data matching, calculate risk assessment values ​​and levels, build monitoring data and push it to the holographic monitoring platform.

Benefits of technology

It realizes holographic monitoring and risk assessment of pharmaceutical suppliers, and can scientifically classify suppliers, improve the accuracy and efficiency of risk identification, and ensure the reliability and accuracy of data.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to the field of pharmaceutical supplier monitoring technology, and specifically to a pharmaceutical supplier holographic monitoring method and system based on risk assessment, which pre-processes the collected target pharmaceutical supplier risk control data to generate target pharmaceutical supplier risk control feature data, performs data search processing with established pharmaceutical supplier risk type feature data to generate target pharmaceutical supplier risk type data, searches for matching weight data from an established pharmaceutical supplier risk type weight data set to obtain target pharmaceutical supplier risk type weight data and calculate target pharmaceutical supplier risk assessment value, compares the target pharmaceutical supplier risk assessment value with a set risk threshold numerically, generates target pharmaceutical supplier risk level data according to the numerical comparison result, and finally constructs target pharmaceutical supplier monitoring data and pushes it to a pharmaceutical supplier holographic monitoring platform, thereby scientifically realizing holographic monitoring and risk assessment of pharmaceutical suppliers.
Need to check novelty before this filing date? Find Prior Art